The release of the snapshot containing the respective simulations can be found here:
[https://github.com/Open-Systems-Pharmacology/Atazanavir-Raltegravir-DDI/releases/tag/v1.1]([https://github.com/Open-Systems-Pharmacology/Atazanavir-Raltegravir-DDI/releases/tag/v1.1).

The atazanavir / raltegravir interaction was evaluated using four clinical DDI studies ([Iwamoto 2008](#4-references), [Krishna 2008](#4-references), [Neely 2010](#4-references), [Zhu 2010](#4-references)).



| DataID | Enzyme | Perpetrator / victim     | Study design                                                 | Clinical study                 |
| ------ | ------ | ------------------------ | ------------------------------------------------------------ | ------------------------------ |
| 571    | UGT1A1 | Atazanavir / raltegravir | Atazanavir: 400 mg once daily dosing<br />Raltegravir: 100 mg single dose on day 7 simultaneous with the 7th dose of atazanavir | [Iwamoto 2008](#4-references)  |
| 575    | UGT1A1 | Atazanavir / raltegravir | Atazanavir: 400 mg once daily dosing<br />Raltegravir: 1200 mg single dose on day 7 simultaneous with the 7th dose of atazanavir | [Krishna 2008,](#4-references) |
| 573    | UGT1A1 | Atazanavir / raltegravir | Atazanavir: 400 mg once daily dosing<br />Raltegravir: 400 mg once daily dosing (control phase 400 mg twice daily)<br />DDI assessment on day 8 | [Neely 2010](#4-references)    |
| 579    | UGT1A1 | Atazanavir / raltegravir | Atazanavir: 300 mg twice daily dosing<br />Raltegravir: 400 mg twice daily dosing <br />DDI assessment on day 27 | [Zhu 2010](#4-references)      |

